Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial

Daily Rifapentine for Treatment of Pulmonary Tuberculosis. A Randomized, Dose-Ranging Trial

(2015) Susan E. Dorman et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis

(2015) Marieke G. G. Sturkenboom et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis

(2014) Emmanuel Chigutsa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin

(2014) C. Magis-Escurra et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients

(2014) Hsien-Chun Lin et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis

(2014) Corinne S. Merle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

(2014) Stephen H. Gillespie et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis

(2014) Amina Jindani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Factors Associated with Death during Tuberculosis Treatment of Patients Co-Infected with HIV at the Yaoundé Central Hospital, Cameroon: An 8-Year Hospital-Based Retrospective Cohort Study (2006–2013)

(2014) Ako A. Agbor et al.   PLoS One

Troubleshooting carry-over of LC–MS/MS method for rifampicin, clarithromycin and metabolites in human plasma

(2013) D.H. Vu et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

(2013) J. G. Pasipanodya et al.   JOURNAL OF INFECTIOUS DISEASES

A Semimechanistic Pharmacokinetic-Enzyme Turnover Model for Rifampin Autoinduction in Adult Tuberculosis Patients

(2012) Wynand Smythe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization

(2012) D. H. Vu et al.   CURRENT PHARMACEUTICAL DESIGN

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy

(2012) Junichi Azuma et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

(2012) Rovina Ruslami et al.   LANCET INFECTIOUS DISEASES

Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients

(2011) Siv Jönsson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability

(2011) Shashikant Srivastava et al.   JOURNAL OF INFECTIOUS DISEASES

New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability

(2010) T. Gumbo   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography–tandem mass spectrometry

(2009) Femke de Velde et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Biowaiver monographs for immediate release solid oral dosage forms: Rifampicin

(2009) C. Becker et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ethambutol Dihydrochloride**This paper reflects the scientific opinion of the authors and not the policies of regulating agencies.**A project of the International Pharmaceutical Federation FIP, Groupe BCS, http://www.fip.org/bcs.

(2007) C. Becker et al.   JOURNAL OF PHARMACEUTICAL SCIENCES